

Publications

Dr. Simon Frey

Peer-reviewed

- 2016 **Frey S**, Blankart CR, & Stargardt T, 2016. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. *PharmacoEconomics*, 34(5), 479–498. [IF 2.450] [8 Link](#)
- 2016 Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PWP, **Frey S**, ... Hellmich M, 2016. Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework. *Expert Review of Pharmacoeconomics & Outcomes Research*, 16(5), 619–627. [8 Link](#) [IF 1.669]
- 2015 Achelrod D, Wenzel U & **Frey S**, 2015. Systematic Review and Meta-Analysis of the Prevalence of Resistant Hypertension in Treated Hypertensive Populations. *American Journal of Hypertension*, 28(3), 355–361. [IF 3.402] [8 Link](#)
- 2014 **Frey S**, 2014. The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching. *European Psychiatry*, 29(8), 479–489. [IF 3.285] [8 Link](#)
- 2014 **Frey S**, Linder R, Juckel G, Stargardt T, 2014. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia – a Markov model parameterized using administrative data. *The European Journal of Health Economics*, 15(2):133–142. [IF 2.095] [8 Link](#)
- 2012 **Frey S**, Stargardt T, 2012. Performance of Compliance and Persistence Measures in Predicting Clinical and Economic Outcomes Using Administrative Data from German Sickness Funds. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 32(10):880–889. [IF 2.311] [8 Link](#)
- 2009 Bufe A, **Frey S**, Briswalter S, 2009. Costs Caused by Bleeds within the Therapy of Acute Coronary Syndromes in Germany [German]. *Herz*, 34(6):479–484. [IF 0.894] [8 Link](#)

Non peer-reviewed

- 2013 **Frey S**, Schreyögg J, 2013. Lexikon Gesundheitsökonomie: Markov-Modellierung [German]. *Gesundheitsökonomie & Qualitätsmanagement*, 18(2): 64.